Intra-cellular Therapies, Inc. (ITCI)
$65
Insights on Intra-cellular Therapies, Inc.
Increasing Revenue
Revenue is up for the last 17 quarters, 882.51K → 144.86M (in $), with an average increase of 24.1% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -28.57M → -15.24M (in $), with an average increase of 87.4% per quarter
Vs CTLT
In the last 1 year, Catalent, Inc. has given 72.3% return, outperforming this stock by 69.1%
Performance
- $64.93$66.88$65.00
0.11%
Downside
Day's Volatility :2.92%
Upside
2.81%
- $45.50$84.89$65.00
30.0%
Downside
52 Weeks Volatility :46.4%
Upside
23.43%
Returns
| Period | Intra-cellular Therapies, Inc. | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | -11.8% | 0.5% | 0.0% |
6 Months | 11.0% | 14.1% | 0.0% |
1 Year | 3.21% | 11.9% | 0.0% |
3 Years | 74.08% | 18.7% | -20.0% |
Highlights
Market Capitalization | 7.0B |
Book Value | $6.15 |
Earnings Per Share (EPS) | -1.16 |
PEG Ratio | 0.0 |
Wall Street Target Price | 91.64 |
Profit Margin | -21.57% |
Operating Margin TTM | -14.46% |
Return On Assets TTM | -11.23% |
Return On Equity TTM | -18.07% |
Revenue TTM | 513.9M |
Revenue Per Share TTM | 5.34 |
Quarterly Revenue Growth YOY | 52.0% |
Gross Profit TTM | 95.2M |
EBITDA | -131.4M |
Diluted Eps TTM | -1.16 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.53 |
EPS Estimate Next Year | 1.16 |
EPS Estimate Current Quarter | -0.32 |
EPS Estimate Next Quarter | -0.2 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 40.98%
Technicals Summary
Sell
Neutral
Buy
Intra-cellular Therapies, Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Intra-cellular Therapies, Inc. | -9.72% | 11.0% | 3.21% | 74.08% | 428.89% |
 Neurocrine Biosciences Inc. | 7.36% | 30.03% | 49.98% | 51.68% | 85.56% |
 Haleon Plc Spon Ads | 4.67% | 3.15% | 0.35% | 14.84% | 14.84% |
 Zoetis Inc. | 13.68% | -1.14% | -3.15% | 2.32% | 70.28% |
 Viatris Inc. | -1.26% | 15.95% | 17.18% | -31.59% | -32.8% |
 Catalent, Inc. | -0.77% | 38.67% | 72.28% | -44.82% | 22.04% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Intra-cellular Therapies, Inc. | NA | NA | 0.0 | -0.53 | -0.18 | -0.11 | NA | 6.15 |
Neurocrine Biosciences Inc. | 38.56 | 38.56 | 0.44 | 4.12 | 0.18 | 0.1 | NA | 23.72 |
Haleon Plc Spon Ads | 28.86 | 28.86 | 1.69 | 0.46 | 0.07 | 0.04 | 0.03 | 1.8 |
Zoetis Inc. | 33.47 | 33.47 | 2.58 | 5.77 | 0.5 | 0.14 | 0.01 | 11.07 |
Viatris Inc. | 224.4 | NA | NA | 2.74 | 0.0 | 0.03 | 0.04 | 16.81 |
Catalent, Inc. | 211.02 | NA | 2.06 | 0.37 | -0.28 | -0.01 | NA | 19.96 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Intra-cellular Therapies, Inc. | Buy | $7.0B | 428.89% | NA | -21.57% |
Neurocrine Biosciences Inc. | Buy | $14.3B | 85.56% | 38.56 | 18.65% |
Haleon Plc Spon Ads | Buy | $38.2B | 14.84% | 28.86 | 9.64% |
Zoetis Inc. | Buy | $79.3B | 70.28% | 33.47 | 27.38% |
Viatris Inc. | Hold | $13.1B | -32.8% | 224.4 | -0.37% |
Catalent, Inc. | Hold | $10.0B | 22.04% | 211.02 | -28.44% |
Institutional Holdings
FMR Inc
10.88%Vanguard Group Inc
8.63%BlackRock Inc
7.78%Wasatch Advisors LP
3.44%Bellevue Group AG
2.91%venBio Select Advisor LLC
2.14%
Corporate Announcements
Intra-cellular Therapies, Inc. Earnings
Intra-cellular Therapies, Inc.’s price-to-earnings ratio stands at None
Read More
Company Information
intra-cellular therapies is a company based out of 3960 broadway, new york, new york, united states.
Organization | Intra-cellular Therapies, Inc. |
Employees | 610 |
CEO | Dr. Sharon Mates Ph.D. |
Industry | Health Technology |
